- Report
- February 2023
- 164 Pages
Global
From €7120EUR$7,500USD£6,006GBP
- Report
- January 2024
- 200 Pages
Global
From €3940EUR$4,150USD£3,323GBP
- Report
- January 2024
- 200 Pages
Global
From €3940EUR$4,150USD£3,323GBP
- Report
- November 2019
- 153 Pages
Asia Pacific
From €8539EUR$8,995USD£7,203GBP
- Report
- December 2023
- 265 Pages
Global
From €3418EUR$3,600USD£2,883GBP
- Report
- October 2018
- 15 Pages
Global
From €9493EUR$10,000USD£8,008GBP
- Report
- November 2022
- 43 Pages
Global
From €3323EUR$3,500USD£2,803GBP
- Report
- October 2022
- 307 Pages
Global
From €2373EUR$2,500USD£2,002GBP
The Respiratory Syncytial Virus (RSV) Vaccine is a type of respiratory drug used to prevent infection from the RSV virus. It is typically administered to infants and young children, as well as to adults who are at high risk of developing severe RSV infection. The vaccine works by stimulating the body’s immune system to produce antibodies that can fight off the virus. It is usually given in two doses, with the second dose given one month after the first.
The RSV Vaccine market is a growing sector of the respiratory drugs market. It is estimated that the global RSV Vaccine market will reach a value of over $1 billion by 2025. The market is driven by increasing awareness of the virus and its potential to cause severe illness, as well as the development of new vaccines.
Some of the major companies in the RSV Vaccine market include GlaxoSmithKline, Merck, Pfizer, Sanofi, and Novavax. Show Less Read more
